Alpha-Lipoic Acid · supplement
Evidence tier: weak
A universal antioxidant with strong evidence for diabetic nerve pain and insulin resistance.
Alpha lipoic acid is a mitochondrial cofactor for pyruvate dehydrogenase and other dehydrogenase complexes, that much is settled biochemistry. The supplement rationale, that it acts as a both water soluble and fat soluble antioxidant, regenerates glutathione and vitamins C and E, and thereby reduces the oxidative stress driving diabetic nerve damage, is a coherent laboratory hypothesis and is why the trials were run. The trials then largely failed to show the predicted benefit, which is the strongest possible reminder that a good mechanism is not an outcome.
Weak, and this is a case where the best evidence actively argues AGAINST the flagship claim rather than merely failing to support it. Diabetic neuropathy is alpha lipoic acid's strongest indication, so it is the one to test. The 2024 Cochrane review (Baicus and colleagues, PMID 38205823) pooled three placebo controlled randomised trials in 816 adults treated for at least six months and concluded: alpha lipoic acid 'probably has little or no effect on neuropathy symptoms' at six months on the Total Symptom Score (mean difference 0.16 points, 95 percent CI 0.83 to 0.51), and the certainty of THAT finding is MODERATE. It 'may have little or no effect on impairment' at six months on the Neuropathy Impairment Score for the Lower Limbs (mean difference 1.02 points, 95 percent CI 2.93 to 0.89), low certainty. The confidence interval for symptoms did not come close to the minimal clinically important difference of 0.97 points. Read that carefully: this is not an absence of evidence, it is moderate certainty evidence of little or no effect on the thing the product is sold for. The positive literature the seed is leaning on is real but shorter, smaller and often intravenous rather than oral; a 2024 network meta analysis and several 2023 pooled analyses report modest short term symptom relief at 600 to 1,800 mg daily, but reviewers consistently rate certainty low to moderate and flag risk of bias and heterogeneity, and objective nerve function measures typically do not move. Cochrane also noted that ALL of its included studies had high attrition bias. Insulin sensitivity, the seed's second claim, has a thinner base still. Safety is the one genuinely reassuring column: NIH LiverTox assigns alpha lipoic acid a likelihood score of E, unlikely to cause clinically apparent liver injury, with no published reports at standard doses, and Cochrane found probably little or no difference from placebo in adverse events leading to treatment cessation (moderate certainty).
600 mg daily is the dose used in most of the neuropathy trials, including those Cochrane pooled, and short term studies have gone to 1,800 mg daily. No regulator has established a dose for a health outcome, because no regulator has established the outcome. LiverTox notes that alpha lipoic acid has not been approved by the FDA as therapy for any medical disease or condition.
300 to 600 mg twice daily on an empty stomach. R-ALA is the active isomer.
May lower blood sugar, caution with antidiabetic medications. Chelates heavy metals.
Pregnancy: caution
Breastfeeding: caution
Active compounds: alpha-lipoic acid, R-lipoic acid, dihydrolipoic acid
Remedies using Alpha-Lipoic Acid · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.